Home/Filings/4/0001209191-18-008030

4//SEC Filing

Li Bin 4

Accession 0001209191-18-008030

CIK 0000850261other

View on SEC.gov Company Profile

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 8:35 AM ET

Size

34.0 KB

Accession

0001209191-18-008030

Insider Transaction Report

Form 4

Period: 2018-02-05

Sorrento Therapeutics, Inc.SRNE

Ally Bridge Group Capital Partners II, L.P.

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540

ABG II-SO Ltd

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432

Ally Bridge LB Healthcare Master Fund Ltd

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)

Holdings

Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540
Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441

Ally Bridge LB Management Ltd

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540
Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441

Ally Bridge Group Innovation Capital Partners III, L.P.

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540

ABG Management Ltd

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540

Yu Fan

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432

ABG SRNE Ltd

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540

Li Bin

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540

ABG Innovation-SO Ltd

10% Owner

Transactions

Sale
Common Stock
2018-02-05$8.00/sh−16,265$130,182→ 1,310,588 total(indirect: Through ABG II-SO Limited)
Sale
Common Stock
2018-02-05$8.00/sh−37,483$300,006→ 3,041,759 total(indirect: Through ABG SRNE Limited)
Sale
Common Stock
2018-02-05$8.00/sh−16,973$135,848→ 1,408,027 total(indirect: Through ABG Innovation-SO Limited)

Holdings

Warrants
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-06-07→ Common Stock (540,540 underlying)
540,540
Common Stock
(indirect: Through Ally Bridge LB Healthcare Master Fund Limited)
1,991,441
Warrants
(indirect: Through ABG SRNE Limited)
Exercise: $8.50Exp: 2019-05-31→ Common Stock (432,432 underlying)
432,432

Footnotes (10)

[F1]The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act").
[F10]The warrants are exercisable at any time on or after June 7, 2016.
[F2]The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (iv) Ally Bridge LB Management Limited, a Cayman Islands limited company, (v) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) ABG Innovation-SO Limited, a British Virgin Islands limited company,
[F3](ix) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (x) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
[F4]Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
[F5]ABG II-SO directly owns 1,310,588 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
[F6]ABG LB directly owns (i) 1,991,441 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
[F7]ABG SRNE directly owns (i) 3,041,759 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
[F8]Ally Bridge Group Innovation Capital Partners III, L.P. is the owner of the sole voting share of ABG Innovation-SO Limited, which directly owns 1,408,027 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
[F9]The warrants are exercisable at any time on or after May 31, 2016.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Sorrento Therapeutics, Inc.

CIK 0000850261

→

Entity typeother

Related Parties

filerCIK 0001668219

Filing Metadata

Form type: 4
Filed: Feb 6, 7:00 PM ET
Accepted: Feb 7, 8:35 AM ET
Size: 34.0 KB

View on SEC.gov